I agree in part. A leak from the FDA is highly unlikely, IMO; however, I think many large investors are aware of the 5-year anniversary of MNTA's Copaxone ANDA acceptance and may be wondering how much more time the FDA can possibly need to complete the review.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”